GB Sciences, Inc. (GBLX)
USD 0.0
(-8.0%)
USD 0.0
(-8.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -975.69 Thousand | -1.52 Million | -1.86 Million | -2.18 Million | -4.47 Million | -9.23 Million |
| Net Income | -1.36 Million | -4.12 Million | -915.21 Thousand | -4.11 Million | -11.63 Million | -24.68 Million |
| Depreciation & Amortization | 624.00 | 61.66 Thousand | 70.48 Thousand | 47.35 Thousand | 258.72 Thousand | 622.96 Thousand |
| Deferred income taxes | - | 20.19 Billion | - | 580.87 Thousand | 1.4 Million | 22.01 Thousand |
| Stock-based compensation | 219.16 Thousand | 17.33 Thousand | 60.66 Thousand | 436.34 Thousand | 287.26 Thousand | 3.81 Million |
| Change in working capital | 402.76 Thousand | 85.05 Thousand | 68.62 Thousand | -270.65 Thousand | 4 Million | 4.46 Million |
| Other non-cash items | -173.75 Thousand | -20.19 Billion | -1.15 Million | 1.13 Million | 1.2 Million | 6.51 Million |
| Investing Cash Flow | 320 Thousand | -31.65 Thousand | 1.45 Million | 4.65 Million | -538.78 Thousand | -11.63 Million |
| Investments in PPE | -2.00 | -31.65 Thousand | -200 Thousand | -292.67 Thousand | -294.15 Thousand | -10.58 Million |
| Acquisitions | - | - | 1.64 Million | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 320 Thousand | -31.65 | 1567.00 | 4.94 Million | -244.62 Thousand | -1.04 Million |
| Financing Cash Flow | 557.77 Thousand | 1.43 Million | -495.92 Thousand | -1.47 Million | 4.98 Million | 17.51 Million |
| Debt repayment | -322 Thousand | -48.82 Thousand | -575 Thousand | -3.3 Million | -106.04 Thousand | -809.17 Thousand |
| Dividends payments | - | - | - | - | - | -2861.43 Billion |
| Common Stock Repurchased | - | - | - | - | - | -809.17 Thousand |
| Common Stock Issuance | 235.77 Thousand | 1.48 Million | 138.72 Thousand | 1.07 Million | 790.22 Thousand | 10.44 Million |
| Other Financing Activities | 557.77 Billion | 1.48 Million | -59.65 Thousand | 756.1 Thousand | 4.3 Million | 2861.44 Billion |
| Accounts receivables | - | - | - | - | 412.49 Thousand | 172.89 Thousand |
| Accounts payables | 157.59 Thousand | -20.19 Thousand | 821.25 Thousand | -248.11 Thousand | 781.58 Thousand | 2.69 Million |
| Inventory | - | - | - | - | 665.56 Thousand | -749.45 Thousand |
| Other working capital | 245.16 Thousand | 105.25 Thousand | -752.62 Thousand | -22.54 Thousand | 2.14 Million | 2.34 Million |
| Cash at beginning of period | 109.91 Thousand | 233.89 Thousand | 1.14 Million | 151.76 Thousand | 182.05 Thousand | 3.57 Million |
| Cash at end of period | 11.99 Thousand | 109.91 Thousand | 233.89 Thousand | 793.04 Thousand | 151.76 Thousand | 227.75 Thousand |
| Capital Expenditure | -2.00 | -31.65 Thousand | -200 Thousand | -292.67 Thousand | -294.15 Thousand | -10.58 Million |
| Effect of forex changes on cash | - | -123.98 Billion | - | -352.59 Thousand | - | - |
| Net cash flow / Change in cash | -97.92 Thousand | -123.98 Thousand | -911.74 Thousand | 641.27 Thousand | -30.28 Thousand | -3.35 Million |
| Free Cash Flow | -975.7 Thousand | -1.55 Million | -2.06 Million | -2.47 Million | -4.77 Million | -19.82 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -467.04 Thousand | -1.36 Million | -187.27 Thousand | -434.23 Thousand | -273.12 Thousand | -4.12 Million |
| Depreciation & Amortization | - | 624.00 | - | - | 624.00 | 61.66 Thousand |
| Deferred income taxes | - | - | - | - | - | 20.19 Billion |
| Stock-based compensation | - | 219.16 Thousand | - | 219.16 Thousand | - | 17.33 Thousand |
| Change in working capital | 214.57 Thousand | 402.76 Thousand | 56.19 Thousand | 22.06 Thousand | 109.92 Thousand | 85.05 Thousand |
| Other non-cash items | -119.93 Thousand | -173.75 Thousand | -74.32 Thousand | -219.52 Thousand | 57.27 Thousand | -20.19 Billion |
| Investing Cash Flow | - | 320 Thousand | 85 Thousand | 235 Thousand | - | -31.65 Thousand |
| Investments in PPE | -2.00 | - | - | - | - | -31.65 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 320 Thousand | 85 Thousand | 235 Thousand | - | -31.65 |
| Financing Cash Flow | 247 Thousand | 557.77 Thousand | 33.33 Thousand | 252.44 Thousand | 25 Thousand | 1.43 Million |
| Debt repayment | -247 Thousand | -322 Thousand | - | -50 Thousand | -25 Thousand | -48.82 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -17.75 Thousand | - | - | - | - | - |
| Common Stock Issuance | -17.75 Thousand | 235.77 Thousand | 33.33 Thousand | 220.19 Thousand | - | 1.48 Million |
| Other Financing Activities | 17.75 Thousand | 557.77 Billion | 1.00 | 82.24 Thousand | 50 Thousand | 1.48 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 119.93 Thousand | 157.59 Thousand | 28.6 Thousand | -75.13 Thousand | 84.19 Thousand | -20.19 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -7724.00 | 245.16 Thousand | 27.59 Thousand | 97.19 Thousand | -84.19 Thousand | 105.25 Thousand |
| Cash at beginning of period | 17.45 Thousand | 109.91 Thousand | 104.53 Thousand | 29.61 Thousand | 109.91 Thousand | 233.89 Thousand |
| Cash at end of period | 11.99 Thousand | 11.99 Thousand | 17.45 Thousand | 104.53 Thousand | 29.61 Thousand | 109.91 Thousand |
| Capital Expenditure | -2.00 | - | - | - | - | -31.65 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | -123.98 Billion |
| Net cash flow / Change in cash | -5468.00 | -97.92 Thousand | -87.07 Thousand | 74.91 Thousand | -80.3 Thousand | -123.98 Thousand |
| Free Cash Flow | -252.47 Thousand | -975.69 Thousand | -205.4 Thousand | -412.52 Thousand | -105.3 Thousand | -1.55 Million |
MOTILALOFS
SVRS
300326
LXCHEM
RXMD
MOREPENLAB